Serine/threonine protein kinase
From Proteopedia
(Difference between revisions)
| Line 255: | Line 255: | ||
**[[1wxm]] – hA-Raf RAS-binding domain - NMR<br /> | **[[1wxm]] – hA-Raf RAS-binding domain - NMR<br /> | ||
| - | *'''B-Raf''' | + | *'''B-Raf'''; domains - Ras-binding 153-237; kinase 445-723 |
**[[1uwh]], [[3c4c]] – hB-Raf kinase domain + anticancer drug<br /> | **[[1uwh]], [[3c4c]] – hB-Raf kinase domain + anticancer drug<br /> | ||
**[[1uwj]] – hB-Raf kinase domain (mutant) + anticancer drug<br /> | **[[1uwj]] – hB-Raf kinase domain (mutant) + anticancer drug<br /> | ||
| - | **[[2fb8]], [[3d4q]], [[3ii5]], [[3psd]], [[3skc]], [[3tv6]], [[4g9c]], [[4ksp]], [[4ksq]], [[3psb]], [[3ppj]], [[3ppk]], [[3prf]], [[3pri]], [[3tv4]], [[4dbn]], [[4e4x]], [[4mbj]], [[4ehe]], [[3q4c]], [[3q96]], [[3e26]], [[4h58]], [[4e26]], [[4fc0]], [[4pp7 | + | **[[2fb8]], [[3d4q]], [[3ii5]], [[3psd]], [[3skc]], [[3tv6]], [[4g9c]], [[4ksp]], [[4ksq]], [[3psb]], [[3ppj]], [[3ppk]], [[3prf]], [[3pri]], [[3tv4]], [[4dbn]], [[4e4x]], [[4mbj]], [[4ehe]], [[3q4c]], [[3q96]], [[3e26]], [[4h58]], [[4e26]], [[4fc0]], [[4pp7]], [[6cad]] – hB-Raf kinase domain + pyrazole inhibitor<br /> |
| - | + | ||
**[[4jvg]], [[4ehg]], [[4fk3]], [[3idp]], [[4g9r]], [[4wo5]], [[4mnf]], [[4r5y]], [[4rzv]], [[4rzw]], [[4xv1]], [[4xv2]], [[4xv3]], [[4xv9]], [[4yht]], [[5c9c]], [[5hi2]], [[5ita]], [[5jrq]], [[5jsm]], [[5jt2]] – hB-Raf kinase domain (mutant) + pyrazole inhibitor<br /> | **[[4jvg]], [[4ehg]], [[4fk3]], [[3idp]], [[4g9r]], [[4wo5]], [[4mnf]], [[4r5y]], [[4rzv]], [[4rzw]], [[4xv1]], [[4xv2]], [[4xv3]], [[4xv9]], [[4yht]], [[5c9c]], [[5hi2]], [[5ita]], [[5jrq]], [[5jsm]], [[5jt2]] – hB-Raf kinase domain (mutant) + pyrazole inhibitor<br /> | ||
| + | **[[5csw]], [[5csx]], [[5ct7]], [[5fd2]], [[5hid]], [[5hie]], [[5val]], [[5vam]], [[6b8u]] - hB-Raf kinase domain + inhibitor<br /> | ||
**[[4mne]] – hB-Raf kinase domain + MAPKK1<br /> | **[[4mne]] – hB-Raf kinase domain + MAPKK1<br /> | ||
**[[2l05]], [[5j17]], [[5j2r]] – hB-Raf RAS-binding domain - NMR<br /> | **[[2l05]], [[5j17]], [[5j2r]] – hB-Raf RAS-binding domain - NMR<br /> | ||
| Line 286: | Line 286: | ||
**[[3uc4]], [[3uc3]], [[3udb]], [[3zut]], [[3zuu]] – AtChk Srk2E kinase domain (mutant) – ''Arabidopsis thaliana''<br /> | **[[3uc4]], [[3uc3]], [[3udb]], [[3zut]], [[3zuu]] – AtChk Srk2E kinase domain (mutant) – ''Arabidopsis thaliana''<br /> | ||
**[[3ujg]] – AtChk Srk2E kinase domain (mutant) + protein phosphatase 2C<br /> | **[[3ujg]] – AtChk Srk2E kinase domain (mutant) + protein phosphatase 2C<br /> | ||
| + | **[[5yks]] – hChk<br /> | ||
| - | *'''MAPK-interacting Chk''' | + | *'''MAPK-interacting Chk''' or Mnk1 Mnk2 |
**[[2hw6]] – hChk 1 catalytic domain<br /> | **[[2hw6]] – hChk 1 catalytic domain<br /> | ||
**[[2hw7]] – hChk 1 catalytic domain + staurosporin<br /> | **[[2hw7]] – hChk 1 catalytic domain + staurosporin<br /> | ||
| - | **[[2ac3]] – hChk 2<br /> | + | **[[5wvd]] – hChk 1 catalytic domain + inhibitor<br /> |
| - | **[[2ac5]] – hChk 2 (mutant)<br /> | + | **[[2ac3]] – hChk 2 catalytic domain<br /> |
| + | **[[2ac5]] – hChk 2 catalytic domain (mutant)<br /> | ||
| + | **[[6cj5]], [[6cje]], [[6cjh]], [[6cjw]], [[6cjy]], [[6ck3]], [[6ck6]], [[6cki]] – hChk 2 catalytic domain (mutant) + inhibitor<br /> | ||
*'''hChk Pak''' | *'''hChk Pak''' | ||
**[[1f3m]] – hChk Pak-1 autoregulatory+kinase domains<br /> | **[[1f3m]] – hChk Pak-1 autoregulatory+kinase domains<br /> | ||
| - | **[[4otd]] - hChk Pak-1 | + | **[[4otd]] - hChk Pak-1 kinase domain<br /> |
**[[1yhv]], [[1yhw]], [[3q4z]], [[3q52]], [[3q53]] – hChk Pak-1 kinase domain (mutant)<br /> | **[[1yhv]], [[1yhw]], [[3q4z]], [[3q52]], [[3q53]] – hChk Pak-1 kinase domain (mutant)<br /> | ||
**[[4o0r]], [[4o0t]], [[4zji]], [[4zjj]], [[4zlo]], [[4zy4]], [[4zy5]], [[4zy7]], [[5ime]], [[5kbq]], [[5kbr]], [[6b16]] – hChk Pak-1 kinase domain + inhibitor<br /> | **[[4o0r]], [[4o0t]], [[4zji]], [[4zjj]], [[4zlo]], [[4zy4]], [[4zy5]], [[4zy7]], [[5ime]], [[5kbq]], [[5kbr]], [[6b16]] – hChk Pak-1 kinase domain + inhibitor<br /> | ||
| Line 305: | Line 308: | ||
**[[2qme]] – hChk Pak-1 CRIB domain + RAC3<br /> | **[[2qme]] – hChk Pak-1 CRIB domain + RAC3<br /> | ||
**[[3fxz]], [[3fy0]], [[4daw]] – hChk Pak-1 kinase domain (mutant) + Ru complex<br /> | **[[3fxz]], [[3fy0]], [[4daw]] – hChk Pak-1 kinase domain (mutant) + Ru complex<br /> | ||
| + | **[[6fd3]] – hChk Pak-3 kinase domain (mutant)<br /> | ||
**[[2j0i]], [[4fie]] – hChk Pak-4<br /> | **[[2j0i]], [[4fie]] – hChk Pak-4<br /> | ||
**[[4fig]], [[4fij]], [[4l67]] – hChk Pak-4 kinase domain<br /> | **[[4fig]], [[4fij]], [[4l67]] – hChk Pak-4 kinase domain<br /> | ||
| Line 324: | Line 328: | ||
**[[4ow8]] - MtChk PknA kinase domain <br /> | **[[4ow8]] - MtChk PknA kinase domain <br /> | ||
**[[3ori]], [[3ork]], [[3orl]], [[3orm]], [[3oro]], [[3orp]], [[3ort]] - MtChk PknB kinase domain (mutant) <br /> | **[[3ori]], [[3ork]], [[3orl]], [[3orm]], [[3oro]], [[3orp]], [[3ort]] - MtChk PknB kinase domain (mutant) <br /> | ||
| - | **[[ | + | **[[1o6y]] – MtChk PknB kinase domain<br /> |
| - | **[[ | + | **[[6b2p]], [[6b2q]] – MtChk PknB kinase domain + inhibitor<br /> |
| - | **[[2kud]], [[2kue]], [[2kuf]], [[2kui]] – MtChk PknB pasta domains - NMR<br /> | + | **[[2kud]], [[2kue]], [[2kuf]], [[2kui]] – MtChk PknB pasta domains 2-3 - NMR<br /> |
| + | **[[3ouv]] – MtChk PknB pasta domain 3<br /> | ||
**[[5e0y]] – MtChk PknB pasta domain 4<br /> | **[[5e0y]] – MtChk PknB pasta domain 4<br /> | ||
**[[5e10]] – MtChk PknB pasta domains 1-2<br /> | **[[5e10]] – MtChk PknB pasta domains 1-2<br /> | ||
| Line 345: | Line 350: | ||
**[[4b9d]] - hChk Nek1 kinase domain (mutant) + inhibitor<br /> | **[[4b9d]] - hChk Nek1 kinase domain (mutant) + inhibitor<br /> | ||
**[[2w5h]] – hChk Nek2 kinase domain<br /> | **[[2w5h]] – hChk Nek2 kinase domain<br /> | ||
| - | **[[2jav]], [[2wqo]], [[2xk3]], [[2xk4]], [[2xk6]], [[2xk7]], [[2xk8]], [[2xkc]], [[2xkd]], [[2xke]], [[2xkf]], [[2xnm]], [[2xnn]], [[2xno]], [[2xnp]], [[4a4x]], [[4afe]], [[5m51]], [[5m53]], [[5m55]], [[5m57]] – hChk Nek2 + inhibitor<br /> | + | **[[2jav]], [[2wqo]], [[2xk3]], [[2xk4]], [[2xk6]], [[2xk7]], [[2xk8]], [[2xkc]], [[2xkd]], [[2xke]], [[2xkf]], [[2xnm]], [[2xnn]], [[2xno]], [[2xnp]], [[4a4x]], [[4afe]], [[5m51]], [[5m53]], [[5m55]], [[5m57]], [[6h0o]] – hChk Nek2 + inhibitor<br /> |
**[[2w5a]], [[2w5b]] – hChk Nek2 + nucleotide<br /> | **[[2w5a]], [[2w5b]] – hChk Nek2 + nucleotide<br /> | ||
**[[2wqm]] – hChk Nek7<br /> | **[[2wqm]] – hChk Nek7<br /> | ||
**[[2wqn]] – hChk Nek7 + ADP<br /> | **[[2wqn]] – hChk Nek7 + ADP<br /> | ||
**[[5de2]] – hChk Nek7 + hChk Nek9<br /> | **[[5de2]] – hChk Nek7 + hChk Nek9<br /> | ||
| + | **[[6gt1]], [[2wqo]] – hChk Nek7 + inhibitor<br /> | ||
*hChk Vrk (vaccinia-related kinase) | *hChk Vrk (vaccinia-related kinase) | ||
| Line 356: | Line 362: | ||
**[[3op5]] – hChk Vrk1 kinase domain (mutant)<br /> | **[[3op5]] – hChk Vrk1 kinase domain (mutant)<br /> | ||
**[[5ukf]] – hChk Vrk1 kinase domain + inhibitor<br /> | **[[5ukf]] – hChk Vrk1 kinase domain + inhibitor<br /> | ||
| - | **[[5uvf]] – hChk Vrk1 kinase domain (mutant) + inhibitor<br /> | + | **[[5uvf]], [[6cnx]], [[6bu6]], [[6cfm]], [[6dd4]], [[6bp0]], [[6bru]], [[6btw]], [[6cmm]], [[6cqh]], [[6csw]] – hChk Vrk1 kinase domain (mutant) + inhibitor<br /> |
**[[2v62]] – hChk Vrk2 kinase domain <br /> | **[[2v62]] – hChk Vrk2 kinase domain <br /> | ||
**[[5uu1]] – hChk Vrk2 kinase domain + inhibitor<br /> | **[[5uu1]] – hChk Vrk2 kinase domain + inhibitor<br /> | ||
| Line 363: | Line 369: | ||
**[[2lru]] – rChk Wnk1 autoinhibitory domain - NMR<br /> | **[[2lru]] – rChk Wnk1 autoinhibitory domain - NMR<br /> | ||
| + | **[[5w7t]] - rChk Wnk1 kinase domain <br /> | ||
**[[3fpq]], [[4q2a]], [[4pwn]] - hChk Wnk1 kinase domain (mutant)<br /> | **[[3fpq]], [[4q2a]], [[4pwn]] - hChk Wnk1 kinase domain (mutant)<br /> | ||
| - | **[[5wdy]], [[5we8]] - hChk Wnk1 kinase domain + inhibitor<br /> | + | **[[5tf9]] - hChk Wnk1 kinase domain + inhibitor + AMPPNP<br /> |
| + | **[[5wdy]], [[5we8]] - hChk Wnk1 kinase domain + inhibitor + ANP<br /> | ||
**[[5drb]] - rChk Wnk1 kinase domain (mutant) + inhibitor<br /> | **[[5drb]] - rChk Wnk1 kinase domain (mutant) + inhibitor<br /> | ||
| + | **[[6fbk]] - hChk Wnk2 CCT1 domain + AMPPNP <br /> | ||
**[[5o1v]], [[5o21]], [[5o23]] - hChk Wnk3 kinase domain <br /> | **[[5o1v]], [[5o21]], [[5o23]] - hChk Wnk3 kinase domain <br /> | ||
**[[5o2c]] - hChk Wnk3 kinase + CCT1 domains <br /> | **[[5o2c]] - hChk Wnk3 kinase + CCT1 domains <br /> | ||
| Line 375: | Line 384: | ||
**[[4efo]] – hChk Tbk1 ubiquitin-like domain <br /> | **[[4efo]] – hChk Tbk1 ubiquitin-like domain <br /> | ||
**[[4im0]], [[4im2]], [[4im3]], [[4iw0]], [[4iwo]], [[4iwp]], [[4ipq]] – hChk Tbk1 (mutant) + inhibitor <br /> | **[[4im0]], [[4im2]], [[4im3]], [[4iw0]], [[4iwo]], [[4iwp]], [[4ipq]] – hChk Tbk1 (mutant) + inhibitor <br /> | ||
| + | **[[5w5v]] – hChk Tbk1 + amlexanox <br /> | ||
**[[4eut]], [[4euu]] – hChk Tbk1 kinase+ubiquitin-like domains (mutant) + inhibitor <br /> | **[[4eut]], [[4euu]] – hChk Tbk1 kinase+ubiquitin-like domains (mutant) + inhibitor <br /> | ||
| + | **[[5eoa]], [[5eof]] – hChk Tbk1 residues 677-729 + optineurin <br /> | ||
**[[4jl9]], [[4jlc]] – mChk Tbk1 + inhibitor <br /> | **[[4jl9]], [[4jlc]] – mChk Tbk1 + inhibitor <br /> | ||
| Line 382: | Line 393: | ||
**[[2rse]] – hChk Mtor + FKBP1A - NMR <br /> | **[[2rse]] – hChk Mtor + FKBP1A - NMR <br /> | ||
**[[4drh]], [[4dri]], [[4drj]], [[5gpg]] – hChk Mtor FRB domain + FKBP + rapamycin <br /> | **[[4drh]], [[4dri]], [[4drj]], [[5gpg]] – hChk Mtor FRB domain + FKBP + rapamycin <br /> | ||
| - | **[[4jsn]], [[4jsp]], [[4jsv]], [[4jsx]], [[4jt5]], [[4jt6]] – hChk Mtor + target of rapamycin complex<br /> | + | **[[5wbh]] – hChk Mtor FRB domain + S6K1 peptide <br /> |
| + | **[[4jsn]], [[4jsp]], [[4jsv]], [[4jsx]], [[4jt5]], [[4jt6]] – hChk Mtor residues 1376-2549 + target of rapamycin complex<br /> | ||
| + | **[[5wby]], [[5wbu]] – hChk Mtor residues 1376-2549 + target of rapamycin complex + proline-rich Akt1 substrate<br /> | ||
**[[5flc]] – hChk Mtor complex 1 – Cryo EM <br /> | **[[5flc]] – hChk Mtor complex 1 – Cryo EM <br /> | ||
**[[5h64]] – hChk Mtor complex 1 + LST8 – Cryo EM <br /> | **[[5h64]] – hChk Mtor complex 1 + LST8 – Cryo EM <br /> | ||
| + | **[[5zcs]] – hChk Mtor complex 2 – Cryo EM <br /> | ||
*'''Haspin''' | *'''Haspin''' | ||
Revision as of 18:22, 18 September 2018
| |||||||||||
3D structures of serine/threonine protein kinase
Updated on 18-September-2018
References
- ↑ Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003 May;3(5):421-9. PMID:12781359
- ↑ Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res. 2004 Nov 15;301(1):60-7. PMID:15501446 doi:http://dx.doi.org/10.1016/j.yexcr.2004.08.016
- ↑ Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene. 2005 Jan 10;24(2):287-91. PMID:15640844 doi:http://dx.doi.org/10.1038/sj.onc.1208272
- ↑ Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 2009 Jun;28(1-2):51-63. doi: 10.1007/s10555-008-9168-1. PMID:19165420 doi:http://dx.doi.org/10.1007/s10555-008-9168-1
- ↑ Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 2007 Aug;64(15):1930-44. PMID:17530463 doi:http://dx.doi.org/10.1007/s00018-007-7045-7
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089
- ↑ Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017. PMID:22500797 doi:http://dx.doi.org/10.1016/j.cell.2012.03.017
- ↑ Ravindran R, Loebbermann J, Nakaya HI, Khan N, Ma H, Gama L, Machiah DK, Lawson B, Hakimpour P, Wang YC, Li S, Sharma P, Kaufman RJ, Martinez J, Pulendran B. The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation. Nature. 2016 Mar 24;531(7595):523-7. doi: 10.1038/nature17186. Epub 2016 Mar 16. PMID:26982722 doi:http://dx.doi.org/10.1038/nature17186
- ↑ Atilla-Gokcumen GE, Di Costanzo L, Meggers E. Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3beta. J Biol Inorg Chem. 2010 Sep 7. PMID:20821241 doi:10.1007/s00775-010-0699-x

